Gold prices edge higher on raised Fed rate cut hopes
NEW ORLEANS - Aptamer Group plc (AIM:APTA), a developer of synthetic binders for the life sciences, revealed new data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting demonstrating the potential of its Optimer therapeutic delivery vehicle to target fibrotic diseases in various organs.
The latest findings, showcased between May 13-17 in New Orleans, indicate that the Optimer can effectively target fibrosis not only in the liver but also in the kidney, skin, lung, and heart. This versatility suggests the Optimer could serve as a universal platform for a variety of precision therapies addressing different fibrotic conditions.
Aptamer’s recent in-house studies and collaboration with AstraZeneca (NASDAQ:AZN) have shown that the Optimer delivery system can carry multiple siRNA molecules, making it adaptable for various therapeutic applications. The capability to target multiple tissue types with different therapeutic cargos expands its commercial potential significantly.
Dr. Arron Tolley, CEO of Aptamer Group, commented on the breadth of the asset’s applicability, emphasizing the opportunity to address a wide range of diseases beyond the primary focus on liver fibrosis, which is driven by a large market size and limited existing treatments. The Optimer’s adaptability to other fibrotic diseases like pulmonary, renal, cardiac, and dermal fibrosis could substantially increase its commercial reach.
The liver fibrosis treatment market is expected to grow at a compound annual growth rate of 24% through 2035, fueled by new drugs in development and an increasing prevalence of the disease. This growth presents Aptamer with an opportunity to capitalize on the expanding market.
Aptamer Group’s ongoing partnership with AstraZeneca has been producing compelling data, and the interest it has garnered has led to discussions with multiple pharmaceutical companies about potential partnerships in the coming months.
The information in this article is based on a press release statement from Aptamer Group plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.